Clincosm LogoSign in Get a demo

TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment

Sponsor
Centers for Disease Control and Prevention (U.S. Fed)
Overall Status
Completed
CT.gov ID
NCT00023439
Collaborator
US Department of Veterans Affairs (U.S. Fed)
300
Enrollment
14
Locations
21.4
Patients Per Site

Study Details

Study Description

Brief Summary

This is a pilot study to evaluate the performance of several nucleic acid amplification methodologies in the diagnosis and management of active tuberculosis

Condition or Disease Intervention/Treatment Phase
  • Other: Nucleic Acid Amplification Methods for diagnosis

Detailed Description

This study evaluates potential surrogate markers of treatment failure and relapse as a substudy of ongoing Tuberculosis Trials Consortium (TBTC) disease treatment studies. After enrollment is complete, specimens from cases of treatment failure and relapse will be evaluated in comparison to control samples to measure the prognostic value of the following tests: 1) quantitative rRNA in 2-month sputum to predict relapse, 2) MTB 85B mRNA to detect reactivation, 3) 1- to 4-month NAA and broth culture tests to predict relapse, 4) mRNA, rRNA and DNA at and after end of therapy to predict relapse, 5)sputum rRNA and blood DNA to detect recurrence during prodrome, 6) sputum rRNA compared to cultures to diagnose "paradoxical reactions," 7) compare blood DNA to cultures at end of induction and end of treatment, 8) compare accuracies of different NAA assays and standard cultures, 9) determine MTD rRNA assay positive to negative conversion time, 10) characterize quality and quantity of sputum over time in relation to culture and clinical outcome, 11) assess ability of clinical, radiographic, and microbiologic risk factors to predict treatment failure and relapse.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Time Perspective:
Prospective
Official Title:
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Study Start Date :
May 1, 2000

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. (1) Enrollment in another TBTC treatment study, or (2) Suspected or culture-confirmed pulmonary TB (designated "NAA2"). Acceptable as indicators of suspected tuberculosis -- culture -- will be a positive AFB smear or a positive M. tuberculosis NAA test for MTB.

    2. (For NAA2 cases only): Collection of a sputum specimen for NAA processing, obtained in the interval from 14 days before, to 17 days after the start of anti-tuberculosis treatment.

    3. Physician recommendation and patient willingness to receive tuberculosis therapy as described in another TBTC treatment trial or in accordance with CDC/ATS recommendations as outlined below:

    Induction phase therapy will be initiated with 4-drugs (isoniazid, PZA, rifamycin and either ethambutol or streptomycin) by directly observed therapy (DOT).

    • The induction regimen:

    1. Induction regimens must have at least 40 DOT doses (if daily) or at least 56 DOT daily dose equivalents (if twice weekly). No more than 2 of every 7 total doses may be self-administered. Total induction doses (both DOT and self-administered) should not exceed 70. Induction should be completed within 12 weeks

    2. The ethambutol or streptomycin may be discontinued if the patient continues on adequate induction therapy with INH, rifampin and PZA, and if the M. tuberculosis isolate is susceptible to INH and rifampin.

    • If this induction regimen is not tolerated by the patient, a rifampin-containing regimen compatible with CDC/ATS recommendations is an acceptable alternative.

    1. Age 18 years or older

    2. Willingness to practice effective contraception (if female and of child-bearing potential)

    3. Provision of written informed consent. Signed by both the patient and investigator, in accordance with Institutional Review Board requirements

    Exclusion Criteria:

    • Treatment with a drug(s) with high anti-mycobacterial activity for more than 15 days in the two months PRIOR to the start of anti-tuberculosis treatment, unless co-enrolled in TBTC Study 23, TBTC Study 24 or another TBTC treatment study.

    • Patients with only extrapulmonary tuberculosis, unless co-enrolled in TBTC Studies 23, TBTC Study 24, or another TBTC treatment study.

    • Skeletal tuberculosis

    • Silicotuberculosis

    • Patient intolerance of rifamycins, or MTB resistance to rifamycins

    • Pregnancy or breast feeding

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Central Arkansas Veterans Health System Little Rock Arkansas United States 72205
    2 LA County/USC Medical Center Los Angeles California United States 90033
    3 University of California, San Francisco San Francisco California United States 94110
    4 Denver Department of Public Health and Hospitals Denver Colorado United States 80204
    5 Emory University School of Medicine Atlanta Georgia United States 30303
    6 Chicago-Lakeside VAMC Chicago Illinois United States 60611
    7 Harlem Hospital Center New York New York United States 10037
    8 University of North Texas Health Science Center Fort Worth Texas United States 76107-2699
    9 Audi L. Murphy VA Hospital San Antonio Texas United States 78284
    10 Seattle King County Health Department Seattle Washington United States 98104
    11 University of British Columbia Vancouver British Columbia Canada Canada V5Z 4R4
    12 University of Manitoba Winnipeg Manitoba Canada CANADA R3A 1R8
    13 Nelson R. Mandela School of Medicine Durban KwaZulu Natal South Africa
    14 Makerere University Medical School Kampala Uganda

    Sponsors and Collaborators

    • Centers for Disease Control and Prevention
    • US Department of Veterans Affairs

    Investigators

    • Principal Investigator: Marc Weiner, MD, Audie L. Murphy VA Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00023439
    Other Study ID Numbers:
    • CDC-NCHSTP-2530
    • NAA TBTC
    First Posted:
    Sep 10, 2001
    Last Update Posted:
    Aug 3, 2011
    Last Verified:
    Jun 1, 2011
    Keywords provided by , ,
    tuberculosis
    TB
    Additional relevant MeSH terms:
    Tuberculosis

    Study Results

    No Results Posted as of Aug 3, 2011